MA40498A - Méthode de traitement de l'intoxication par organophosphates - Google Patents

Méthode de traitement de l'intoxication par organophosphates

Info

Publication number
MA40498A
MA40498A MA040498A MA40498A MA40498A MA 40498 A MA40498 A MA 40498A MA 040498 A MA040498 A MA 040498A MA 40498 A MA40498 A MA 40498A MA 40498 A MA40498 A MA 40498A
Authority
MA
Morocco
Prior art keywords
treatment
organophosphate poisoning
organophosphate
poisoning
Prior art date
Application number
MA040498A
Other languages
English (en)
Inventor
Doodipala Samba Reddy
Original Assignee
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A & M Univ Sys filed Critical Texas A & M Univ Sys
Publication of MA40498A publication Critical patent/MA40498A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA040498A 2014-09-02 2015-09-01 Méthode de traitement de l'intoxication par organophosphates MA40498A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462044635P 2014-09-02 2014-09-02

Publications (1)

Publication Number Publication Date
MA40498A true MA40498A (fr) 2021-05-19

Family

ID=55440310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040498A MA40498A (fr) 2014-09-02 2015-09-01 Méthode de traitement de l'intoxication par organophosphates

Country Status (4)

Country Link
US (1) US10172870B2 (fr)
EP (1) EP3188734A4 (fr)
MA (1) MA40498A (fr)
WO (1) WO2016036724A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028398A2 (fr) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation de crises épileptiques par une polythérapie à l'aide de benzodiazépines et de neurostéroïdes
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
WO2014169831A1 (fr) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci
CA2909546C (fr) 2013-04-17 2019-01-22 Sage Therapeutics, Inc. Steroides neuroactifs 19-nor et procedes d'utilisation de ceux-ci
EP3868382A1 (fr) 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Stéroïdes neuroactifs, compositions et leurs utilisations
DK3488852T3 (da) 2013-08-23 2021-02-01 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
WO2015195962A1 (fr) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Stéroïdes neuroactifs, leurs compositions et utilisations
EP3206494A4 (fr) 2014-10-16 2018-07-04 Sage Therapeutics, Inc. Compositions et méthodes pour traiter des troubles du snc
SI3206493T1 (sl) 2014-10-16 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
PL3224269T3 (pl) 2014-11-27 2020-08-24 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
WO2016134301A2 (fr) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Stéroïdes neuroactifs, compositions, et leurs utilisations
EP3377070A4 (fr) * 2015-11-20 2019-07-10 Sage Therapeutics, Inc. Composés et leurs méthodes d'utilisation
WO2018013615A1 (fr) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associées
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
US20210205329A1 (en) * 2018-05-21 2021-07-08 The University Of North Carolina At Chapel Hill Methods of inhibiting proinflammatory neuroimmune signaling and treating inflammatory disorders
CZ309617B6 (cs) 2019-04-05 2023-05-24 Ústav organické chemie a biochemie AV ČR, v. v. i 3α5ß-Neuroaktivní steroidy pro léčbu epilepsie a záchvatových onemocnění
PE20230244A1 (es) 2019-05-31 2023-02-07 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos
WO2021026124A1 (fr) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone destinée à être utilisée dans le traitement de l'état de mal épileptique
BR112022019085A2 (pt) * 2020-03-25 2023-01-31 Sage Therapeutics Inc Uso de agentes para tratamento de condições respiratórias
US12005185B2 (en) 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
DE69422163T2 (de) 1993-02-19 2000-06-15 Nippon Shinyaku Co., Ltd. Glycerolderivat, vorrichtung und pharmazeutische zusammensetzung
EP0701444B1 (fr) 1993-05-24 2010-04-07 Purdue Pharma Ltd. Procedes et compositions induisant le sommeil
ATE195654T1 (de) 1994-02-14 2000-09-15 Euro Celtique Sa Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
NZ298567A (en) 1994-11-23 2000-01-28 Cocensys Inc Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
HUP9901138A3 (en) 1995-06-06 1999-11-29 Cocensys Inc Irvine Neuroactive steroids of the androstane and pregnane series
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
EP1626980A4 (fr) 2003-05-29 2007-07-04 Univ Washington 13,24-cyclo-18,21-dinorcholanes neuroactifs et steroides pentacycliques structurellement associes
JP5663303B2 (ja) 2007-06-15 2015-02-04 リサーチ トライアングル インスティテュート Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド
US20090156650A1 (en) * 2007-09-19 2009-06-18 Serb Composition that comprises at least one oxime and its use in therapeutics
WO2012075286A2 (fr) 2010-12-01 2012-06-07 The Regents Of The University Of California Benzodiazépine intrapulmonaire pour traitement et prévention de crises épileptiques
EP2736919A4 (fr) 2011-07-29 2015-01-14 Univ California Nouveaux stéroïdes substitués en 17b par un hétéroaryle, capables de moduler les récepteurs gabaa
WO2013043985A1 (fr) * 2011-09-23 2013-03-28 The Regents Of The University Of California Huiles comestibles favorisant l'administration de stéroïdes administrés par voie orale
WO2014028398A2 (fr) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation de crises épileptiques par une polythérapie à l'aide de benzodiazépines et de neurostéroïdes
RU2667010C2 (ru) 2012-08-21 2018-09-13 Сейдж Терапьютикс, Инк. Способы лечения эпилепсии или эпилептического статуса
EP2934512B1 (fr) * 2012-12-18 2021-11-24 Kotzker Consulting LLC Utilisation de cannabinoïdes et de terpènes pour le traitement d'une toxicité d'organophosphate et de carbamate

Also Published As

Publication number Publication date
US10172870B2 (en) 2019-01-08
EP3188734A1 (fr) 2017-07-12
WO2016036724A1 (fr) 2016-03-10
US20170246188A1 (en) 2017-08-31
EP3188734A4 (fr) 2018-01-10

Similar Documents

Publication Publication Date Title
MA40498A (fr) Méthode de traitement de l'intoxication par organophosphates
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
MA46771A (fr) Méthode de traitement de tumeur immunothérapeutique
HUE060671T2 (hu) Eljárás fibrotikus betegségek kezelésére
HK1231401A1 (zh) 治療阿爾茨海默氏病的方法
HK1214671A1 (zh) 輔助疾病診療的分析系統、裝置及方法
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
IL253118A0 (en) Methods for treating inflammatory diseases
EP3394032A4 (fr) Composés et méthodes de traitement, de dépistage, et d'identification de composés destinés à traiter les maladies provoquées par des parasites apicomplexes
HK1252037A1 (zh) 治療炎性疾病的方法
PL3277272T3 (pl) Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego
HK1258994A1 (zh) 用於疾病治療的方法
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
MA41462A (fr) Méthode de traitement de maladies
EP3215148A4 (fr) Méthodes pour le traitement d'un déclin cognitif
FR3039368B1 (fr) Procede de traitement cosmetique
FR3034011B1 (fr) Procede de traitement cosmetique des cheveux
HK1256883A1 (zh) 治療多囊腎病的方法
MA41636A (fr) Méthode de traitement de la cholangite sclérosante primitive
FR3039649B1 (fr) Procede de detection d'especes oxydantes
HK1246679A1 (zh) 絲蟲病的治療
HK1243937A1 (zh) 治療疾病的方法
FR3030270B1 (fr) Procede de traitement cosmetique et kit associe
MA51688A (fr) Protéines prohémostatiques pour le traitement de saignement